Clinical research

The randomised study of the double dose versus single dose sirolimus-eluting stent for the treatment of diabetic patients with de novo coronary lesions

EuroIntervention 2006;2:295-301 - DOI10.4244/EIJV2I3A54.

Ricardo Costa
Ricardo A. Costa1, MD; J. Eduardo Sousa2*, MD, PhD; Alexandre Abizaid2, MD, PhD; Áurea Chaves2, MD, PhD; Fausto Feres2, MD, PhD; Amanda G. M. R. Sousa2, MD, PhD; Giuseppe Musumeci3, MD; Roxana Mehran1, MD; Peter J. Fitzgerald4, MD, PhD; Alexandra J. Lansky1, MD; Martin B. Leon1, MD; Avinoam Shiran5, MD; David A. Halon5, MB, ChB; Basil S. Lewis5, MD; Giulio Guagliumi3, MD
1. The Cardiovascular Research Foundation & Columbia University Medical Center, New York, NY, USA; 2. Institute Dante Pazzanese of Cardiology, São Paulo, Brazil; 3. Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy; 4. Stanford Universit

Background: Even though sirolimus-eluting stents (SES) have been shown to significantly improve binary restenosis and target lesion revascularisation rates (TLR) compared to bare metal sten

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

diabetes mellitussirolimus-eluting stentsrestenosistrials
Read next article
Long term outcome of balloon mitral commissurotomy during pregnancy: a prospective physical and mental evaluation of babies

Latest news